NASDAQ:SAGE
Delisted

Sage Therapeutics Stock News

etoro logo Buy SAGE
*Your capital is at risk
$8.68
+0 (+0%)
At Close: Oct 30, 2025

7 of the Best Pharma Stocks to Buy Now

10:37am, Tuesday, 11'th May 2021
As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first o
SAGE Therapeutics, Inc. (SAGE) CEO Barry Greene on Q1 2021 Results - Earnings Call Transcript
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 17.17% and -18.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stoc
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of peopl
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last year in November. SAGE-324, the second major
Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

Knocked Down, These 3 Stocks May Rise Again

10:06am, Monday, 05'th Apr 2021
When stocks are punished, it's not always for a good reason.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
Can this brain health-focused biotech continue to rise, or will it fade -- again?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debili
With the trading day more than halfway over, the broad markets saw a huge pull back on Thursday.
Sage Therapeutics, Inc. (SAGE) CEO Barry Greene on Q4 2020 Results - Earnings Call Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE